Accurate detection of genomic fusions by high-throughput sequencing in clinical samples with 25 inadequate tumor purity and formalin-fixed paraffin embedded (FFPE) tissue is an essential task 26 in precise oncology. We developed the fusion detection algorithm Junction Location Identifier 27 (JuLI) for optimization of high-depth clinical sequencing. We implemented novel filtering steps 28 to minimize false positives and a joint calling function to increase sensitivity in clinical setting. 29
INTRODUCTION 36
High-throughput sequencing is becoming increasingly prevalent in precision cancer medicine 37 worldwide. In the Republic of Korea and United States of America, assays using high-38 throughput sequencing have received regulatory approval as companion diagnostic tests for 39 personalized care 40 (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm33 41 0711.htm, 42 http://www.mohw.go.kr/react/jb/sjb0406vw.jsp?PAR_MENU_ID=03&MENU_ID=030406&CO 43 NT_SEQ=338288&page=1). Most assays use sequencing technology to identify clinically 44 actionable single nucleotide variants (SNVs) and small insertions/deletions (indels) because they 45 are relatively easy to detect and interpret. However, some cancers such as ALK-rearranged non-46 small cell lung cancers (NSCLCs) and BCR/ABL-rearranged chronic myeloid leukemias (CMLs) 47 are driven by somatic genomic fusions that cannot be detected by these methods for SNVs/indels. 48 Patients with these oncogenic fusions respond to tyrosine kinase inhibitors (TKIs), and such 49 genomic changes are now key therapeutic targets (Druker et al. 2001; Awad and Shaw 2014) . 50 results in DNA and RNA damage, which is affected by various preanalytical factors, such as 66 duration of storage, formalin fixation, and ischemic time (Evers et al. 2011; Spencer et al. 2013; 67 Araujo et al. 2015) . These fragmented nucleic acids act as noise and may make it difficult to 68 detect oncogenic fusions. The detection of genomic fusions in clinical samples tends to be 69 challenging because of the above-mentioned problems. 70
As the importance of detecting genomic fusions in clinical decision-making continues to increase, 71 a critical area for improvement is currently the accuracy of detecting actionable fusions for the 72 realization of precision cancer medicine. In the present study, we focused on improving the 73 reliability of detecting somatic actionable fusions in cancer using high-depth DNA sequencing. 74
To address the above problems, we developed a fusion detection algorithm optimized for clinical 75 purposes and validated this algorithm using cancer cell lines with known driver fusions and 459 76 NSCLC samples with known ALK fusion and/or RET fusion status and 46 prostate cancer 77 samples with known TMPRSS2 fusion status ( Supplementary Table 1 ). 78 79 80 MATERIALS AND METHODS 81 7 out, and the remaining reads were sorted using SAMtools (Li et al. 2009 ). To prepare appropriate 125 input BAM files for other callers, we employed MarkDuplicates of Picard (Broad Institute), 126 which is commonly used for marking and removal of duplicate reads (McKenna et al. 2010) . 127 128
Workflow for fusion identification 129
Fusion detection algorithm To identify genomic fusions for clinical applications, we developed 130 an algorithm called Junction Location Identifier (JuLI) with the aim of reducing the number of 131 false positives generated while maintaining sensitivity. Initially, basic statistics of the BAM files, 132 such as read length and median insert size, are calculated and used for further steps. Candidate 133 breaks are then defined using two or more clipped reads, including at least one soft-clipped read, 134 against the genome reference. If a matched normal sample is available as a control, breaks with 135 twice the cutoff value of the clipped reads are scanned in the normal sample, and candidate 136 breaks that overlapped with the breaks in the normal sample are excluded. If a set of normal 137 samples is available, a control panel can be generated using a function in JuLI, which 138 incorporates the breakpoints in multiple samples. All the samples in the present study were 139 processed without matched normal or control panel filtering. The algorithm then involves two 140 separate parts, viz., discordant and split read analyses. The user can set all parameters of each 141 step. 142 143 Discordant read analysis As JuLI does not remove duplicate reads as a part of the algorithm, 144 counting supporting reads is very important to reduce the number of false positive calls. JuLI 145 first uses information, including the genomic positions of both paired reads, CIGAR (Concise 146 Idiosyncratic Gapped Alignment Report) strings, and the QNAME of sequencing reads in the 147 8 BAM file, to reduce redundant duplicated or noise signals. Candidate breaks with fewer than 148 three unique discordant reads are filtered. Next, consensus contigs from the matched and clipped 149 side of each candidate break are generated. The average number of pairwise differences, 150 representing nucleotide diversity (π), between the reads and the consensus contig on both sides 151 of the candidate break is calculated as follows: 152
where N is the number of reads across the break, ρ i is the frequency of the ith read across the 153 break, and π i is the proportion of bases that differ between the read and consensus contig 154 truncated to the read length. If the normalized nucleotide diversity of either the clipped or 155 matched side is higher than 2.0, the break is excluded from further processing. The normalized 156 nucleotide diversity is calculated using the following formulae: 157
where !"#$!!" !"#$ is the mean of nucleotide diversity of matched sides, and S matched side denotes 158 the standard deviation of nucleotide diversity of the matched sides. Candidate breaks that pass 159 the filters described above are paired with each other using the pair information, and split side 160 contigs of each pair are aligned to the matched side contigs of their partners. If one of the two 161 pairs matches more than 70% of the split contig length and is longer than 10 bp, the pair is called 162 a fusion event. If there are no candidate pairs that passed the filters, a fusion event is defined if 163 more than six discordant reads formed a cluster and more than 70% and more than 20 bp of the 164 split contig is mapped to the reference sequence of the cluster region. 165 166 9 Split read analysis Split read and discordant read analyses are conducted similarly. Candidate 167 breaks with fewer than three split reads are filtered and then subjected to the following filtering 168 steps, including nucleotide diversity analysis and pairwise local alignment. As JuLI is based on 169 split information, fusions with a length less than half the read length are not considered. In split 170 read analysis, if both pairs matched ≥70% of the length of the split contigs, the pair is considered 171 a fusion event. 172 173 Joint call analysis The joint call combines information from multiple BAM files in each analysis 174 step and separates the numbers of each supporting read in the final step to produce individual 175 results of the BAM files. If some fusion events have been previously defined in other BAM files, 176 the fusions can be efficiently detected by specifying the target area using the BED (Browser 177 Extensible Data) format. This is extremely useful for the case in cfDNA analysis as acquired 178 serial samples for cfDNA may not have enough supporting reads, which makes it difficult to 179 detect the events (see Discussion). 180 181
Settings of algorithms 182
We carefully studied the documentation for each algorithm to determine and apply 183 parameters that could be optimized in the clinical sample data. 184 JuLI: All analyses were performed using JuLI v.0.1.3 with the default parameters. Fusion events 185 in the UCSC gap database were excluded from further analysis. 186
SvABA: All analyses were performed using SvABA v 134 (Wala et al. 2018) . We applied a -M 187 flag so that the number of "weird reads" was not limited in highly fragmented FFPEs. We 188 employed sorted, indexed, and duplication-free BAMs for SvABA. The command line for the 189 analysis was as follows: We preprocessed BAM files as recommended by the developers (sorting, indexing, and duplicate 193 marking) . We applied the exclusion regions of the hg19 reference included in the Delly source 194 code. The Delly command line for the analysis was as follows We converted the output with BCF (binary variant call format) to VCF (variant call format) 197
using BCFtools, which was included as a submodule in Delly. We selected the results of VCF 198 that passed the quality filter for all analyses. Next, we launched a workflow run script with a single node using the following command line 206 for execution: 207 $ OUTPUT_DIR/runWorkflow.py -m local -j 1 208
We selected the results of VCF that passed the quality filter for all analyses. We applied the 209 high-depth filter parameter for whole-genome sequencing (WGS) analysis. 
Development of a fusion detection algorithm for clinical sequencing 231
Since 2014, we have used a custom-designed panel (CancerSCAN TM ) for precision oncology that 232 covers up to 381 cancer-related genes, including introns containing frequent breakpoints in 233 12 selected fusion genes (Shin et al. 2017) . To obtain high detection rates, we ensured a mean 234 sequencing coverage of approximately 1200X and a target insert size of approximately 180bp in 235 the initial alignment. We have developed several algorithms to improve the accuracy of our 236 platform. For fusion detection, here, we developed JuLI, which was optimized for high-depth 237 sequencing ( Fig. 1a-d fig. S1 ), which may, thus, affect the sensitivity of detecting lower 249 tumor cell content. We carefully counted reads supporting candidate breaks by determining 250 duplicate fragments using CIGAR and pair locations without applying a general deduplication 251 step ( Fig. 1b; see Methods) . Next, the candidates with sufficient supporting reads were 252 subjected to the following two filtering steps. First, we measured nucleotide diversity ( ), which 253 is the average number of pairwise differences between the reads and the consensus contig, and 254 the breaks with high nucleotide diversity were excluded from further processing ( Fig. 1c; see  255 Methods). Second, the candidate break and partner breaks were paired via pair information and 256 13 compared by pairwise local alignments ( Fig. 1d ; see Methods). Through these filtering steps, we 257 were able to accurately detect fusions by reducing the number of false positives. 
Effects of damaged DNA in FFPE tissues 274
As mentioned above, one of the challenges in analyzing clinical samples is that FFPE tissues 275 usually contain degraded DNA and smaller fragment sizes (Spencer et al. 2013) . As a 276 consequence, the ratio of split to total reads is substantially higher in FFPE samples than that in 277 fresh samples examined by CancerSCAN (t test, p < 10 −22 ; Fig. 1e ). To eliminate the differences 278 between individual samples, three pairs of fresh and routinely processed FFPE cancer cell lines 279 were chosen for sequencing to compare tissue effects. Furthermore, differences in the split to 280 total read ratio were also observed ( Fig. 1e ). An increase in the numbers of split reads could 281 affect noise in fusion analyses and may cause numerous false positive events. To compare FFPE 282 effects and for further analysis, we chose several state-of-the-art fusion callers, including SvABA 283 to JuLI. In the comparison of fusion events count, we observed a significant increase in count of 286 fusion events in FFPE tissues when using SvABA, Delly, Manta, LUMPY, and novoBreak ( Fig.  287   1f) . The count of fusion events of JuLI and LUMPY was not affected by the tissue type, but the 288 count of LUMPY was ten-times higher than that of JuLI, regardless of the tissue type ( Fig. 1f) . 289
Analysis of three paired fresh and routine FFPE cancer cell line specimens revealed differences 290 in counts of fusion events between the FFPE and fresh specimens. BHP10-3 revealed the highest 291 change in the split/total read ratio ( Fig. 1e) and showed the highest difference in fusion counts 292 using most callers (Fig. 1f) . Numerous split reads were observed in the FFPE specimen of 293 BHP10-3 probably because of DNA damage during sample preparation ( fig. S2) . For the tools 294 affected by FFPE tissues, the count of fusion events was positively correlated with split/total 295 reads ratio ( fig. S3 ). However, JuLI showed the least increase in the number of fusion events 296 16 with increasing split/total reads ratio ( fig. S3 ). Low quality of FFPE tissue can cause numerous 297 false positive results with most callers, but such quality issues did not significantly affect the 298 results yielded by JuLI. 299 300
Validation of analytical sensitivity on cancer cell lines and patient's samples 301
To evaluate the accuracy of the algorithm over a wide range of tumor purity, we adopted 302 experimental schemes designed by Frampton et al. (Frampton et al. 2013) . To simulate different 303 tumor purity levels, four cancer cell lines harboring known fusions and a normal sample were 304 manually mixed at different ratios, generating a range of expected tumor purity levels (5%-100%) 305
( Supplementary Table 2 ). All cell line specimens were profiled using CancerSCAN TM version 306 1, which targeted 83 genes. The mixed fraction of the fusions showed a high correlation 307
(correlation coefficient [r] = 0.95) with the relative value of the normalized supporting reads ( fig.  308   S4) . We observed that JuLI, SvABA, Delly, Manta, and LUMPY achieved 100% sensitivity 309 (32/32), but novoBreak missed one large deletion between GOPC and ROS1 with 5% mix 310 fraction in this experiment ( Supplementary Table 4 ). In addition, 37 fusions in patients' tissues 311 detected by JuLI with a wide range of supporting reads (range, 6-283) were validated by PCR to 312 verify the estimated fusion breakpoints. The locations of all fusion sequences at the estimated 313 breakpoints were confirmed (Supplementary Table 3) . value (PPV; also known as precision) and sensitivity (also known as recall)] of the callers 319 according to the minimum fusion length in 494 clinical samples examined by CancerSCAN ( Fig.  320   2a and Supplementary Table 1) . Fusion results that are shorter than the minimum length in 321 each caller were excluded from the comparison and the performance comparison criteria are 322 described in the following paragraph. In all ranges of minimum fusion size, we observed that 323
JuLI outperformed other callers. Although JuLI and SvABA were less affected by performance 324 over the range of fusion sizes, Delly exhibited increased performance at a relatively long length 325 of fusion. We observed that Manta, LUMPY, and novoBreak tended to have lower PPV 326 compared to sensitivity ( Supplementary Table 5 ) and a decrease in performance in 327 predominantly FFPE tissues compared to that in fresh tissues ( Supplementary Table 5 ). The 328 minimum length of F1 score saturation for each caller was 800 bp for JuLI and SvABA, 1500 bp 329 for Delly, 1900 bp for Manta, 1200 bp for LUMPY, and 1300 bp for novoBreak. In order to 330 compare except for the regions with different performance, we compared the results except for 331 the fusions with the length shorter than 1250bp, which is the median value of the performance 332 saturation length of each caller. 333 clinical decision-making. Over the last four years, CancerSCAN TM has been used at the oncology 342 18 clinic of SMC. We conducted performance validation in a prospective cohort of 448 patients 343 with NSCLC and profiled ALK and/or RET status by immunohistochemistry (IHC) and/or 344 fluorescence in situ hybridization (FISH) . Of the 441 patients tested for ALK, 9.5% (42/441) 345 were positive, and 67 patients were tested for RET, of which 16.4% (11/67) were positive 346 ( Supplementary Table 1 ). No patient was both ALK-and RET-positive, and the results of the 347 IHC/FISH of ALK and other hotspot mutations in EGFR (L858R or exon 19indel) or KRAS (G12, 348 G13, or Q61) showed a mutually exclusive pattern (Fisher's exact test, p < 10 −11 ). A total of 79 349 patients were profiled using CancerSCAN TM version 1, which targeted 83 genes, whereas the rest 350 were profiled using version 2, which targeted 381 genes (Shin et al. 2017) . Both V1 and V2 351 panels covered the same hotspot introns involved in ALK and RET rearrangement (introns of 352 ALK between exons 19-21 and RET between exons 6-12). 353
As mentioned above, we considered fusion events that were ≥1250 bp in size, and ≥1 breaks 354 were found in the analysis of ALK and RET region. Most ALK and RET activation cases involved 355 the rearrangement or activating mutations that activate the kinase domain; in case of NSCLC, 356 ALK and RET are primarily activated by fusion with various partners (Hallberg and Palmer 2013; 357 Lee et al. 2015; Noh et al. 2017) . Therefore, we assumed intragenic rearrangements in ALK and 358
RET as a false positive. The respective sensitivity and PPV of ALK fusions were as follows: JuLI, 359 90.4% (38/42 samples) and 95.0% (38/40); SvABA, 88.0% (37/42) and 88.0% (37/42); Delly, 360 88.0% (37/42) and 90.2% (37/41); Manta, 83.3% (35/42) and 14.7% (35/238); LUMPY, 88.0% 361 (37/42) and 32.3% (37/115); and novoBreak, 90.4% (38/42) and 28.6% (38/133) ( Fig. 2b) . For 362 RET fusions, JuLI, SvABA, and Delly achieved same sensitivity and PPV [81.8% (9/11 samples) 363 and 81.8% (9/11), respectively]. The sensitivity and PPV of remaining callers were as follows: 364 Manta, 90.9% (10/11) and 28.6% (10/35); LUMPY, 90.9% (10/11) and 62.5% (10/16); and 365 19 novoBreak, 72.7% (8/11) and 53.3% (8/15) ( Fig. 2c) . Six samples that yielded false negative 366 results of ALK and RET in JuLI analysis also tested negative in most callers, and the tumor purity 367 of these samples was significantly lower than that of the test-positive samples ( fig. S5) . 368
Therefore, some false negatives may be due to low tumor purity. Four false positives of ALK and 369 RET identified in JuLI results were observed in all other callers, and the fusions were clearly 370 identified in browser view ( fig. S6) . 371
To further compare other clinically significant fusions, we retrospectively collected 46 archived 372 prostate cancer samples and performed analysis of ERG fusion status by IHC and/or FISH. 373 Twenty-three of the 46 patients (50.0%) were ERG fusion-positive (Supplementary Table 1) . 374
All patients with prostate cancer were profiled using CancerSCAN TM version 1, and the panel 375 covered the hotspot introns between exons 1-6 of TMPRSS2, the most common fusion partner of 376 ERG fusion (Barros-Silva et al. 2013 ). We measured the performance of the callers with the 377 same criteria as those of NSCLC. The respective sensitivity and PPV of ERG fusions were as 378 follows: JuLI, 56.5% (13/23 samples) and 100.0% (13/13); SvABA, 43.5% (10/23) and 83.3% 379 (10/12); Delly, 39.1% (9/23) and 100.0% (9/9); Manta, 95.7% (22/23) and 53.7% (22/41); 380 LUMPY, 100.0% (23/23) and 50.0% (23/46); and novoBreak, 100.0% (23/23) and 50.0% (23/46) 381 (Fig. 2d) . There was no difference in purity distribution between true positive and false negative 382 of JuLI. The relatively low sensitivity of this retrospective set may be due to other partners of 383 ERG that were not targeted (Cancer Genome Atlas Research 2015). Overall, the number of false 384 calls occurred as the split/total read ratio increased, but this issue had less effect in JuLI. Lowering tumor purity reduces detection sensitivity by proportionally reducing the effective 404 range of mutant alleles in tumor cells. In contrast to research samples, requirements for sufficient 405 tumor purity for clinical specimens may not be met; therefore, it is important to have adequate 406 coverage (Shin et al. 2017). 407 We conducted in silico down-sampling experiments (three iterations) using the ALK set of 408
NSCLCs as an alternative method for investigating the effect of sequencing depth on 409 performance. In down-sampling experiments, we observed that the average sensitivity of all the 410 callers improved with increased coverage (Fig. 3a and 3c) . Although sensitivity increased at high 411 coverage, PPV and specificity decreased in Manta, LUMPY, and novoBreak. In contrast, we 412 noticed that JuLI, SvABA, and Delly were less affected by coverage. The F1 score improved in 413 the 50-200× range, which is the typical range used in WGS or whole-exome sequencing (WES) 414 in all callers (Fig. 3b) . By contrast, the F1 score worsened at high depth (1340×) in Manta, 415 LUMPY, and novoBreak, but not in others. Accuracy, which is the proportion of true results 416 (both true positives and true negatives) among all the results, was also maintained at a high-depth 417 range in JuLI, SvABA, and Delly in contrast to the other callers (Fig. 3d) . Thus, we confirmed 418 that sensitivity improved with increased sequencing depth; however, accuracy may decrease 419 owing to increased noise levels above the threshold in some algorithms. To effectively apply 420 22 high-throughput sequencing in a clinical setting, it is necessary to use software optimized to 421 reduce such noise. 422 423 23 
Sensitivity validation using WGS data 434
To estimate the sensitivity based on real WGS data, we downloaded raw FASTQ data of 435 NA12878 from European Nucleotide Archive (ERA172924, 436 https://www.ebi.ac.uk/ena/data/view/PRJEB3381). These data represent approximately 50X 437 coverage, which has been widely used by tools for the estimation of a variety of variation tools. 438
We compared results made by each tool to the truth set by Layer et al. (Layer et al. 2014) , who 439 developed LUMPY in 2014. They provided a truth set containing 4,095 deletions detected by at 440 least one tool in the 50X dataset that were validated by split-read mapping analysis of 441 independent long-read sequencing data from PacBio or Illumina platforms. In this comparison, 442 LUMPY (47.4%; 1942/4095) was the most sensitive, followed by JuLI (41.9%; 1717/4095), 443
SvABA (41.9%; 1716/4095), Delly (38.5%; 1575/4095), Manta (37.9%; 1552/4095), and 444 novoBreak (37.7%; 1542/4095). We were able to confirm that the performance of JuLI was 445 maintained as much as other callers even at a low depth, such as WGS; however, specificity or 446 PPV representing the frequency of false positive calls was not evaluated due to the lack of true 447 negative reference. 448 449 Joint call to detect fusions with insufficient evidence 450
Recent reports have shown that the detection of ALK fusion in cfDNA is feasible in clinic setting 451 (Paweletz et al. 2016; Thompson et al. 2016) . Serial tumor sampling on progression has been 452 helpful in determining the optimal subsequent treatment decision-making for patients. However, 453 this is often complicated by insufficient tumor purity for molecular analysis and tumor 454 heterogeneity (Dagogo-Jack et al. 2018 ). If a more sensitive detection is possible in a series of 455 samples with insufficient supporting reads, slightly earlier decision-making can be made for 456 25 precise medicine. To achieve more sensitive fusion detection in clinical sequencing, we 457 implemented the joint call function in JuLI that can detect fusions with low supporting evidence 458 in serial/multi-region sampling tissues (Fig. 4a) . To verify the performance of this function, in-459 silico down-sampling experiments (mean coverage: 1X, 5X, and 10X with 100 iterations) were 460 performed on mixed cell lines with relatively low cell ratios of 5-40% (Supplementary Table 4) . 461
In this simulation, most callers showed up to 1-2% sensitivity at 10X, joint call showed 40.6% 462 sensitivity at 10X and could detect 7.3% even at 1X ( Supplementary Table 6 ). 463
To confirm the utility of the joint call function of JuLI in clinic, we applied it to ALK detection in 464 cfDNA of NSCLCs. Pleural effusion (PE) and peripheral plasma were collected from four 465 patients with NSCLS, whose ALK status was confirmed in primary tissue (one positive and three 466 negative; Supplementary Table 1 ). DNA of cells in PE, cfDNA of PE, and cfDNA of plasma 467 were processed using LiquidSCAN TM (average coverage, approximately 4300X) and analyzed 468 using the fusion callers. We excluded novoBreak from this analysis because some samples did 469 not show any results in the ultra high-depth data. In this analysis, the callers, except JuLI, missed 470 the EML4/ALK fusion in plasma cfDNA of the ALK-positive patient (CS_LC_0451), but JuLI 471 was able to identify the fusion using the joint call function (Fig. 4b) . There were only two 472 discordant reads supporting the ALK fusion in plasma cfDNA of CS_LC_0451 (Fig. 4c) . 
Annotation and visualization 482
Accurate annotation of rearrangements is critical for clinical decision-making. JuLI annotates 483 functional consequences of genomic fusions that are identified using high-throughput sequencing 484 data in a strand-specific manner ( fig. S7) . Even with breaks at the same location, this annotation 485 approach allows the user to easily distinguish between positive and negative strand events. 486
Moreover, JuLI provides three useful pieces of information. First, JuLI predicts whether the 487 fusion transcript is in-frame or out-of-frame by means of the UCSC database (Kent et al. 2002) . 488
Second, JuLI provides the frequency of fusion events based on cancer types in COSMIC (Forbes 489 et al. 2015) . Third, JuLI annotates chimera protein domains via the UniProt (Apweiler et al. 2004) 490 and Pfam databases (Finn et al. 2010) . Graphically visualized fusion diagrams were 491 automatically generated in PDF format showing all annotation results (Fig. 5) . 
Comparison of running time between paired FFPE and fresh tissues 499
We generated sequencing data from paired FFPE and fresh cancer cell lines using CancerSCAN 500 V1, and of these cell lines, BHP10-3 showed the highest change in the split/total read ratio ( Fig.  501   1e) . To compare elapsed time, we measured BHP10-3 pair analysis time of each caller with 10 502 iterations ( fig. S8) . We observed a 1.1-to 29.3-fold increase in analysis time in low-quality 503 FFPE tissue with these callers. Although JuLI was relatively slow in low quality FFPE tissue 504 because it implements several steps to improve accuracy, the speed can be increased through 505 parallel processing across multiple cores. 506 507 508
DISCUSSION 509
To implement precision medicine at SMC, we developed JuLI, a novel fusion detection 510 algorithm optimized for clinical application. We validated the tool on four cancer cell lines and 511 on 505 clinical tumor specimens. JuLI has several characteristics. First, with the implementation 512 of the noise reduction algorithm to minimize false positive calls, it maintains good analytical 513 specificity without loss of sensitivity, particularly in noisy samples, such as FFPE samples. 514
Second, JuLI can detect fusions with insufficient evidence in serial or multi-region sequencing 515 samples by using the joint call function. Third, JuLI is easy to use with the provided an R 516 package, which is available via GitHub (https://github.com/sgilab/JuLI ) and supports 517 comprehensive annotation and visualization of SVs. 518
An intriguing point is that JuLI can be used for monitoring cancer in specimens such as cfDNA, 519 blood samples of minimal residual leukemic cell follow-up, and follow-up biopsy specimen 520 without ideal tumor purity (Shin et al. 2017 ). Split reads originating from the primary tumor have 521 30 high specificity in the location of fusion junction and adjacent DNA sequences, with uniqueness 522 of split portion. Sensitive calling for these predefined fusion signals in follow-up specimens 523 provided a good chance for early detection of relapsing cancer with good specificity. 524
Clinically, quantitative evaluation of fusion transcript is emphasized in follow-up of some 525 cancers, particularly for CML. Discontinuation of TKIs is suggested in recent NCCN guidelines 526 for CML, and the practice is performed based on quantitative evaluation of the BCR-ABL1 527 transcript. Although the normalization, RNA assay does not provide direct information on the 528 number of malignant clones. However, ultra-high coverage next-generation sequencing (NGS) 529 for DNA fusion could provide direct information on the number of remnant malignant clones in 530 future precision medicine. 531
For accurate detection of tumor-driving fusions, it is assumed to be necessary to detect fusions in 532 both RNA and DNA. RNA is a suitable material for directly detecting chimeric transcripts; 533 however, quality may be compromised because of long storage time or degradation during FFPE 534 preparation (Ludyga et al. 2012) . Detection sensitivity for fusions may be maximized by 535 simultaneously performing DNA and RNA assays. Furthermore, combined fusion analysis for 536 DNA and RNA can help identify loss-of-function of a tumor suppressor gene via fusion or 537 complex fusions involving noncoding regions. 538
The limitation of this study is that a limited number of fusion events were tested for performance 539 validation. Most callers used in this study for comparison reported their results through a 540 genome-wide comparison of several samples in their papers. However, we performed quality 541 (i.e., condition)-wide comparison of 505 patient samples with three clinically important fusion 542 events and four cancer cell lines with known fusions. In a clinical setting, it may be inevitable to 543 31 examine tissues with inappropriate quality (low tumor purity or poor quality FFPE). Therefore, 544
our results could provide useful information to select callers in a clinical setting. 545
In clinical setting, although sensitivity is important, maintaining PPV is also essential to reduce 546 the number of false positives. In particular, if the prevalence is relatively low, such as that of the 547 ALK fusion in NSCLC (2%-7%) (Kwak et al. 2010) , several wrong decisions can be made when 548 PPV is not guaranteed. Clinical decisions based on false test results are risky and may lead to 549 inappropriate treatment strategies. Therefore, if the PPV cannot provide a sufficiently high 550 confidence level, it will be difficult to use the method for diagnostic purposes. Because JuLI has 551 better PPV relative to the existing algorithms, it is likely to deliver accurate fusion profiling data 552 to help clinicians to make optimal therapeutic decisions. 553
